Dr. Charu Aggarwal, MD, MPH

Dr. Aggarwal practices at Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania.

Dr. Aggarwal's NPI, 1114181740, was assigned on July 13, 2008. Dr. Aggarwal holds Pennsylvania license MD435530.

Dr. Aggarwal's primary practice is Hospital of the University of Pennsylvania, at 3400 Spruce St, Philadelphia, PA 19104 in Philadelphia County. The practice phone is (215) 662-6289.

Dr. Aggarwal's primary practice is Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania. Dr. Aggarwal is also affiliated with Penn Presbyterian Medical Center. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Aggarwal to 1 more hospital, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Aggarwal practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Aggarwal's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Aggarwal is licensed in Pennsylvania.

CMS data shows 67 Medicare services from Dr. Aggarwal across 1 procedure code in 2024, all of them office visits, for 55 Medicare patients. Medicare paid $6,834 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 55 Medicare patients who saw Dr. Aggarwal in 2024. The largest group is 65 to 74, with 25 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 2.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Aggarwal's median patient age at 70, with 54% women.

In 2024, Dr. Aggarwal wrote 27 Medicare Part D claims for 13 patients. 63% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $198 in total drug cost. In 2022, CMS named 38 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Aggarwal for performance year 2024, reported as part of a group. Dr. Aggarwal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Aggarwal as offering telehealth.

Dmand AI links 148 papers to Dr. Aggarwal, published from 2015 to 2025. 2023 was the busiest year, with 18. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Aggarwal has published most often in Clin Lung Cancer. Dr. Aggarwal's most frequent co-authors are Corey J. Langer, MD, Joshua Michael Bauml, MD and Lova L. Sun, MD.

CMS Open Payments shows 370 general payments to Dr. Aggarwal from 32 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 88% of the total. AstraZeneca Pharmaceuticals LP paid the most, $344,695. It also lists 3 research payments totaling $10,474 from 2021 to 2024.